Skip to main content
Top
Published in: Gastric Cancer 1/2015

01-01-2015 | Original Article

Trends in the management of gastric cancer over a 32-year period: a French population-based study

Authors: Elodie Herbreteau, Valérie Jooste, Samia Hamza, Côme Lepage, Jean Faivre, Anne-Marie Bouvier

Published in: Gastric Cancer | Issue 1/2015

Login to get access

Abstract

Background

Gastric cancer is still generating interest because of its poor prognosis. The aim of this study was to investigate time trends in diagnostic assessment, patterns of care, and survival of gastric cancers.

Methods

We considered 5,010 gastric cancers diagnosed between 1976 and 2007 in a well-defined French population. Logistic regressions were used to identify factors associated with R0 resection and operative mortality. A multivariate relative survival analysis was performed.

Results

Diagnostic modalities have changed. Since 1988, endoscopy is performed when gastric cancer is suspected (95.5 %). However, there has been no strong variation in stage over time: the proportion of stage I cancers increased from 5.5 % to 13.4 % between the periods 1976–1979 and 2004–2007 (p < 0.001) whereas that of advanced cases remained stable, 64.8 % and 65.0 %, respectively. R0 resections rose from 36.7 % (1976–1979) to 46.7 % between 1980 and 1999, and decreased to 32.7 % thereafter. Age, tumor location, and period were associated with R0 resection. Neoadjuvant and adjuvant chemotherapy were rarely used before 2000, then reached 15.0 % and 19.1 %, respectively, during the later period. Operative mortality after R0 resection decreased from 18.3 % during the 1976–1979 period to 4.3 % during the 2004–2007 period (p < 0.001). Prognosis slightly improved during the three first periods, from 13.0 % to 22.6 %, then leveled off, not exceeding 26.0 % thereafter. Stage, age, histology, and time period significantly influenced survival.

Conclusion

Changes in diagnostic modalities were associated with minor changes in stage and prognosis for gastric cancer. Earlier diagnosis and new therapeutic strategies are the best way to improve the prognosis.
Literature
1.
2.
go back to reference Belot A, Grosclaude P, Bossard N, Jougla E, Benhamou E, Delafosse P, et al. Cancer incidence and mortality in France over the period 1980–2005. Rev Epidemiol Sante Pub. 2008;56:159–75.CrossRef Belot A, Grosclaude P, Bossard N, Jougla E, Benhamou E, Delafosse P, et al. Cancer incidence and mortality in France over the period 1980–2005. Rev Epidemiol Sante Pub. 2008;56:159–75.CrossRef
3.
go back to reference Verdecchia A, Guzzinati S, Francisci S, De Angelis R, Bray F, Allemani C, et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer. 2009;45(6):1042–66.PubMedCrossRef Verdecchia A, Guzzinati S, Francisci S, De Angelis R, Bray F, Allemani C, et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer. 2009;45(6):1042–66.PubMedCrossRef
4.
go back to reference De Vita F, Vecchione L, Galizia G, Di Martino N, Fabozzi T, Catalano G, et al. Perspectives in adjuvant therapy of gastric cancer. Oncology. 2009;77(suppl 1):38–42.PubMedCrossRef De Vita F, Vecchione L, Galizia G, Di Martino N, Fabozzi T, Catalano G, et al. Perspectives in adjuvant therapy of gastric cancer. Oncology. 2009;77(suppl 1):38–42.PubMedCrossRef
5.
go back to reference WHO. International Classification of Disease for Oncology. Third edition. 2000; Geneva: World Health Organization. WHO. International Classification of Disease for Oncology. Third edition. 2000; Geneva: World Health Organization.
6.
go back to reference Siewert JR, Bottcher K, Roder JD, Busch R, Hermanek P, Meyer HJ. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg. 1993;80:1015–8.PubMedCrossRef Siewert JR, Bottcher K, Roder JD, Busch R, Hermanek P, Meyer HJ. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg. 1993;80:1015–8.PubMedCrossRef
7.
go back to reference Dickman P, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med. 2004;23:51–64.PubMedCrossRef Dickman P, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med. 2004;23:51–64.PubMedCrossRef
8.
go back to reference Allum WH, Powell DJ, McConkey CC, Fielding JW. Gastric cancer: a 25-year review. Br J Surg. 1989;76(6):535–40.PubMedCrossRef Allum WH, Powell DJ, McConkey CC, Fielding JW. Gastric cancer: a 25-year review. Br J Surg. 1989;76(6):535–40.PubMedCrossRef
9.
go back to reference Wanebo HJ, Kennedy BJ, Chmiel J, Steele G Jr, Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993;218(5):583–92.PubMedCentralPubMedCrossRef Wanebo HJ, Kennedy BJ, Chmiel J, Steele G Jr, Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993;218(5):583–92.PubMedCentralPubMedCrossRef
10.
go back to reference Fayçal J, Bessaguet C, Nousbaum J, Cauvin J, Cholet F, Bideau K, et al. Epidemiology and long term survival of gastric carcinoma in the French district of Finistere between 1984 and 1995. Gastroenterol Clin Biol. 2005;29(1):23–32.PubMedCrossRef Fayçal J, Bessaguet C, Nousbaum J, Cauvin J, Cholet F, Bideau K, et al. Epidemiology and long term survival of gastric carcinoma in the French district of Finistere between 1984 and 1995. Gastroenterol Clin Biol. 2005;29(1):23–32.PubMedCrossRef
11.
go back to reference Lambert R, Guilloux A, Oshima A, Pompe-Kirn V, Bray F, Parkin M, et al. Incidence and mortality from stomach cancer in Japan, Slovenia and the USA. Int J Cancer. 2002;97(6):811–8.PubMedCrossRef Lambert R, Guilloux A, Oshima A, Pompe-Kirn V, Bray F, Parkin M, et al. Incidence and mortality from stomach cancer in Japan, Slovenia and the USA. Int J Cancer. 2002;97(6):811–8.PubMedCrossRef
12.
go back to reference Schlemper RJ, Itabashi M, Kato Y, Lewin KJ, Riddell RH, Shimoda T, et al. Differences in diagnostic criteria for gastric carcinoma between Japanese and Western pathologists. Lancet. 1997;349(9067):1725–9.PubMedCrossRef Schlemper RJ, Itabashi M, Kato Y, Lewin KJ, Riddell RH, Shimoda T, et al. Differences in diagnostic criteria for gastric carcinoma between Japanese and Western pathologists. Lancet. 1997;349(9067):1725–9.PubMedCrossRef
13.
go back to reference Bouvier AM, Sant M, Verdecchia A, Forman D, Damhuis R, Coebergh JW, et al. What reasons lie behind long-term survival differences for gastric cancer within Europe? Eur J Cancer. 2010;46(6):1086–92.PubMedCrossRef Bouvier AM, Sant M, Verdecchia A, Forman D, Damhuis R, Coebergh JW, et al. What reasons lie behind long-term survival differences for gastric cancer within Europe? Eur J Cancer. 2010;46(6):1086–92.PubMedCrossRef
14.
go back to reference Dassen AE, Lemmens VE, van de Poll-Franse LV, Creemers GJ, Brenninkmeijer SJ, Lips DJ, et al. Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer. 2010;46(6):1101–10.PubMedCrossRef Dassen AE, Lemmens VE, van de Poll-Franse LV, Creemers GJ, Brenninkmeijer SJ, Lips DJ, et al. Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer. 2010;46(6):1101–10.PubMedCrossRef
15.
go back to reference Le A, Berger D, Lau M, El-Serag HB. Secular trends in the use, quality, and outcomes of gastrectomy for noncardia gastric cancer in the United States. Ann Surg Oncol. 2007;14(9):2519–27.PubMedCrossRef Le A, Berger D, Lau M, El-Serag HB. Secular trends in the use, quality, and outcomes of gastrectomy for noncardia gastric cancer in the United States. Ann Surg Oncol. 2007;14(9):2519–27.PubMedCrossRef
16.
go back to reference Lepage C, Sant M, Verdecchia A, Forman D, Esteve J, Faivre J. Operative mortality after gastric cancer resection and long-term survival differences across Europe. Br J Surg. 2010;97(2):235–9.PubMedCrossRef Lepage C, Sant M, Verdecchia A, Forman D, Esteve J, Faivre J. Operative mortality after gastric cancer resection and long-term survival differences across Europe. Br J Surg. 2010;97(2):235–9.PubMedCrossRef
17.
go back to reference Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.PubMedCrossRef Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.PubMedCrossRef
18.
go back to reference Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.PubMedCrossRef Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.PubMedCrossRef
19.
go back to reference Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15(1):261–7.PubMedCrossRef Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15(1):261–7.PubMedCrossRef
20.
go back to reference Piessen G, Messager M, Leteurtre E, Jean-Pierre T, Mariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg. 2009;250(6):878–87.PubMedCrossRef Piessen G, Messager M, Leteurtre E, Jean-Pierre T, Mariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg. 2009;250(6):878–87.PubMedCrossRef
21.
go back to reference Montalban C, Manzanal A, Castrillo JM, Escribano L, Bellas C. Low grade gastric B-cell MALT lymphoma progressing into high grade lymphoma. Clonal identity of the two stages of the tumour, unusual bone involvement and leukemic dissemination. Histopathology (Oxf). 1995;27(1):89–91.CrossRef Montalban C, Manzanal A, Castrillo JM, Escribano L, Bellas C. Low grade gastric B-cell MALT lymphoma progressing into high grade lymphoma. Clonal identity of the two stages of the tumour, unusual bone involvement and leukemic dissemination. Histopathology (Oxf). 1995;27(1):89–91.CrossRef
Metadata
Title
Trends in the management of gastric cancer over a 32-year period: a French population-based study
Authors
Elodie Herbreteau
Valérie Jooste
Samia Hamza
Côme Lepage
Jean Faivre
Anne-Marie Bouvier
Publication date
01-01-2015
Publisher
Springer Japan
Published in
Gastric Cancer / Issue 1/2015
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-014-0342-6

Other articles of this Issue 1/2015

Gastric Cancer 1/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.